{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only.', '5.4.3.3', 'Visit SFU-3 (Week 126 or 22 Weeks after the Last Dose of the Study Treatment)', 'The following assessments will be conducted 22 weeks after the last dose of the study', 'treatment:', 'Record AEs/SAEs', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform complete physical examination.', 'Perform 12-lead ECG.', 'Collect samples for INR, aPTT, and fibrinogen.', 'Collect samples for lipid panel and CV risk panel.', 'Collect samples for chemistry panel, hematology assessments, ANAs, and dsDNA', 'antibodies.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect sample for urinalysis.', '5.4.4', 'Unscheduled Visit', \"It is at the Investigator's discretion to initiate an Unscheduled Visit, if deemed necessary by\", \"the Investigator for the subject's safety and well-being. At this visit, any of the assessments\", 'from the Schedule of Events may be performed dependent on the presenting reason.', \"R-Pharm International's designee should be informed of these incidents in a timely fashion.\", '5.5', 'Subject Diary', 'At Visit 1 (OLE Baseline/Week 24), a Subject Diary will be distributed to all subjects and', 'subjects will be trained to properly complete the Subject Diary.', 'Amendment 2: 06 March 2019', '73', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'At Visit 1 (OLE Baseline/Week 24) and at each scheduled visit during the open-label', 'Treatment Period (Visits 2 [Week 26] through 9 [Week 88]), the Investigator will provide the', 'subject with preprinted dates for each dose of study treatment that will be administered prior', 'to the next scheduled visit. Visit 2 date and further CREDO 4 visit dates should be', 'calculated from the actual CREDO 4 Randomization date. Following each administration of', 'study treatment, the subject will record the actual date, time, and location of study treatment', 'administration in the Subject Diary; the identity of the person who administered the study', 'treatment; any problems that occur during the injection; and any complaints, signs, or', 'symptoms that occur during or after the injection.', 'The Subject Diary will instruct subjects to contact the Investigator if they experience any', 'problems with the injection or if they experience any significant signs or symptoms during or', 'after the injection.', 'The Investigator will collect completed pages of the Subject Diary at Visits 2 (Week 26)', 'through 10 (EoT/Week 106). Completed pages of the Subject Diary will serve as source', 'documents, and the Investigator will transfer the data, including the date, time, and location', 'of each SC injection; the identity of the person who administered the study treatment; and', 'any departures from the intended regimen from the Subject Diary into the appropriate page(s)', 'of the eCRF. The Investigator will also review any complaints, signs, or symptoms recorded', 'in the Subject Diary and record any AEs in the eCRF, as appropriate.', 'The Subject Diary will not be used during the Safety Follow-Up Period.', 'Amendment 2: 06 March 2019', '74', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '6. STUDY TREATMENTS', '6.1', 'Study Treatment Administered', 'Study Treatment', 'All eligible subjects will be randomized to 1 of the 2 OKZ treatment groups as described in', 'Sections 5.2 and 6.5. A detailed description of the study treatment (OKZ) is provided in', 'Section 6.2.', 'Background Therapy', 'As per inclusion criterion No. 3 (see Section 5.3.1), subjects must have been treated with', 'MTX at a dose of 15 to 25 mg/week (or >10 mg/week if there is documented intolerance to', 'higher doses) during the core study with a stable dose and mode of administration (oral, SC,', 'or IM). For the first 12 weeks of the OLE study (i.e., through Week 36), the dose of MTX', 'should remain unchanged and may be adjusted only for safety reasons according to', 'Investigator discretion (see guidelines in Appendix 1 [see Section 13.1]). After Visit 4', '(Week 36), the Investigator may adjust the MTX dosage and route, per local guidelines.', 'Subjects who were prescribed rescue medication(s) (sulfasalazine and/or', 'hydroxychloroquine) during the core studies will be asked to continue these medications at', 'the same dose for the first 12 weeks of the OLE study (i.e., through Visit 4 [Week 36]).', 'After Visit 4 (Week 36), the Investigator may adjust these background medications if deemed', 'appropriate.', 'Additional details regarding background therapy, including adjustments to background', 'therapy that are permitted after Visit 4 (Week 36), are provided in Section 6.13.3.', '6.2', 'Identity of Study Treatment', 'Olokizumab will be supplied by R-Pharm International or its designee.', '6.2.1', 'Olokizumab', 'Olokizumab is a humanized (CDR-grafted) mAb of the IgG4/kappa isotype with the serine in', 'the heavy chain hinge region being replaced with a proline residue. The OKZ drug substance', 'consists of a preparation of purified recombinant humanized mAb (CDP6038; L04041)', 'presented as a solution of 160 mg/mL OKZ in 30 mM histidine hydrochloride, 60 mM', 'sodium chloride, 200 mM sorbitol, and 0.03% polysorbate 80 at pH 5.6. The OKZ drug', 'substance is the fully formulated product, which is sterilized by filtration and aseptically', 'filled in vials or syringes to obtain the drug product.', 'Amendment 2: 06 March 2019', '75', 'Confidential']\n\n###\n\n", "completion": "END"}